Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 2 studies described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

Sitagliptin

Core clinician-reference fields are available or not applicable.

Participants received canagliflozin for 26 weeks.

Canagliflozin

Participants received canagliflozin 100 mg/day ( n =23) for 26 weeks.

Participants received sitagliptin for 26 weeks.

Participants received sitagliptin 100 mg/day ( n =22) for 26 weeks.

Canagliflozin improves myocardial fibrosis in type 2 diabetes

Available source content was suppressed because validation identified a conflict.

Standard care excluding SGLT2is

Participants received canagliflozin 100 mg once daily.

Canagliflozin group

A total of 98 eligible participants were randomized 1:1 to receive canagliflozin 100 mg once daily (canagliflozin group; n = 50) or to receive guideline-recommended standard care excluding the use of SGLT2is (control group; n = 48).

Participants received guideline-recommended standard care excluding the use of SGLT2is.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Canagliflozin slows kidney function decline in type 2 diabetes.

Placebo

Participants received once-daily CT-868 1.75 mg for 26 weeks.

CT-868 1.75 mg

Participants were randomized (1:2:1) to once-daily CT-868 1.75 mg, 4.0 mg, or placebo.

Participants received once-daily CT-868 4.0 mg for 26 weeks.

CT-868 4.0 mg

Participants received a regimen-matched placebo for 26 weeks.

Authoritative quality diagnostic: sample size arm total mismatch.

Canagliflozin × HbA1c

Available supporting studies

Canagliflozin improves myocardial fibrosis in type 2 diabetes

Canagliflozin slows kidney function decline in type 2 diabetes.

CT-868 Improves Glycaemic Control in Type 2 Diabetes